| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th December 2020 | Bros. Advisors Lp Baker | 1,386,033 | Open or private sale | $220.50 | $305,620,276.50 |
| 4th December 2020 | Bros. Advisors Lp Baker | 125,513 | Open or private sale | $220.50 | $27,675,616.50 |
| 20th November 2020 | Jason Ehrlich | 981 | Open or private sale | $138.56 | $135,927.36 |
| 20th November 2020 | Jason Ehrlich | 57 | Open or private sale | $140.88 | $8,029.88 |
| 20th November 2020 | Jason Ehrlich | 2,134 | Open or private sale | $139.39 | $297,453.99 |
| 20th November 2020 | Jason Ehrlich | 400 | Open or private sale | $137.27 | $54,906.80 |
| 20th November 2020 | Jason Ehrlich | 2,614 | Open or private sale | $139.96 | $365,865.90 |
| 20th November 2020 | Jason Ehrlich | 505 | Open or private sale | $133.71 | $67,525.07 |
| 20th November 2020 | Jason Ehrlich | 259 | Open or private sale | $134.72 | $34,892.22 |
| 20th November 2020 | Jason Ehrlich | 6,950 | Exercise of derivative | $10.29 | $71,515.50 |
Kodiak Sciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.
Ticker: KOD
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1468748
Employees: 39
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $270 M (0%)
Marketable Securities, Current: $147 M (18%)
Assets, Current: $419 M (23%)
Property, Plant and Equipment, Net: $1 M (11%)
Other Assets, Noncurrent: $8 M (49%)
Assets: $429 M (19%)
Accounts Payable, Current: $7 M (168%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $19 M (60%)
Other Liabilities, Noncurrent: $276 Th (-6%)
Liabilities: $120 M (789%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $45 M (0%)
Additional Paid in Capital, Common Stock: $517 M (2%)
Retained Earnings (Accumulated Deficit): $209 M (31%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $594 Th (5840%)
Stockholders' Equity (Parent): $309 M (0%)
Liabilities and Equity: $429 M (19%)
Research and Development: $21 M (-49%)
General and Administrative Expenses: $6 M (-47%)
Operating Income/Loss: $27 M (-48%)
News
Small Caps Record A New High, Finally, With More To Come
23rd November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
